By Dr Séverine Fagète (Mammalian Cell Line Development)2024-04-05T09:55:24
The commercial production of recombinant proteins, such as antibodies and enzymes, relies on generating and maintaining specific cell lines designed to produce these specialised molecules. However, the creation of cell lines is a technically demanding and time-consuming process. For this reason, many businesses seek partnerships with contract development and manufacturing ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-02T15:00:00Z 2026-06-02T16:00:00Z
Sponsored by Danaher Life Sciences
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2024-01-26T13:22:42
Sponsored by bit.bio
2023-02-23T14:02:18
Sponsored by bit.bio
2023-03-30T12:35:58
Sponsored by Sartorius
Site powered by Webvision Cloud